More news from American Diabetes Association meeting

Ongoing news from the American Diabetes Association meeting in Philadelphia (see also The Pharma Letter June 11) provided updates on French drug major Sanofi’s (Euronext: SAN) already marketed diabetes drug Lantus (insulin glargine) and Eli Lilly (NYSE: LLY) and German independent drugmaker Boehringer Ingelheim’s LY2605541.

Sanofi reported results from the landmark ORIGIN trial (n=12,500) showing that Lantus had no statistically significant positive or negative impact on cardiovascular outcomes versus standard care in pre- and early diabetes patients during the study period. Data also indicated that insulin glargine delayed progression and there was no association between insulin glargine use and increased risk of any cancer. These findings were presented at the ADA and published online in NEJM. Source: Company press release.

The Paris-based company also revealed new results at the ADA meeting of a large-scale epidemiological program providing additional evidence that there was no increased risk of cancer in diabetes people treated with Lantus compared to those treated with other insulins.